Rallybio Corp (RLYB) — 10-Q Filings
All 10-Q filings from Rallybio Corp. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Rallybio Swings to Profit on JV Sale, R&D Costs Plummet
— Nov 6, 2025 Risk: high
Rallybio Corp (RLYB) reported a net income of $16.016 million for the three months ended September 30, 2025, a significant improvement from a net loss of $11.46 -
Rallybio Reports Zero Revenue, Continued Burn in Q2
— Aug 7, 2025 Risk: high
Rallybio Corp reported no collaboration and license revenue for the three and six months ended June 30, 2025, consistent with the prior year periods. The compan -
Rallybio Corp Q1 2025 Update: Equity Changes Detailed
— May 8, 2025 Risk: medium
Rallybio Corp reported its first quarter 2025 results, ending March 31, 2025. The company's financial statements show changes in its equity accounts, including -
Rallybio Corp Q3 2024: Zero Revenue Continues
— Nov 7, 2024 Risk: medium
Rallybio Corp filed its 10-Q for the period ending September 30, 2024. The company reported collaboration and license revenue of $0 for the third quarter of 202 -
Rallybio Corp Files Q2 2024 10-Q
— Aug 8, 2024 Risk: medium
Rallybio Corp filed its 10-Q for the period ending June 30, 2024, reporting financial results and business updates. The company, focused on developing therapies -
Rallybio Corp Files 10-Q for Period Ending March 31, 2024
— May 9, 2024 Risk: low
Rallybio Corp (RLYB) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Rallybio Corp reported financial results for the quarter ended March 31, 2024.
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX